Tezepelumab as an add-on maintenance treatment is recommended as an option for severe asthma in people 12 years and over, when treatment with high-dose inhaled corticosteroids plus another maintenance treatment has failed.
It is recommended only if people:
Tezepelumab should be discontinued if the rate of severe asthma exacerbations, or the maintenance oral corticosteroid dose, have not been reduced by at least 50% at 12 months.
Clinical impact:
Clinical trial results show that tezepelumab, when added to usual treatment, reduces exacerbations and the dose of oral corticosteroids needed, compared with placebo. An indirect comparison of tezepelumab with other biological treatments suggests similar clinical effectiveness, but this is uncertain.
Economic impact:
The cost-effectiveness estimates show that Tezepelumab as an add-on maintenance therapy is cost effective compared with standard care and other biological (benralizumab, mepolizumab, reslizumab, dupilumab and omalizumab) treatments.
From Skepticism to Support: Healthcare Providers’ Acceptance of Digital Interventions in SUD Treatment in Kenya💡
Healthcare providers in Kenya show high acceptance of digital interventions for substance use disorder treatment. Learn more about how technology is shaping healthcare delivery.
#SyenzaNews #HealthcareInnovation #DigitalInterventions #SubstanceUseDisorder #KenyaHealthcare 🏥💻
📢 #SyenzaNews: The FDA is modernising regulations for AI medical devices with a firm-based approach. This shift focuses on the quality systems of manufacturing firms rather than individual product mechanics.
Discover how this new method can enhance safety and foster innovation in healthcare.
Read more here.
#LifeSciences #HealthcareInnovation #AIMedicalDevices #FDARegulations #HealthTech
Abu Dhabi is making remarkable progress in healthcare through strategic partnerships with leading institutions like CHOP and Penn Medicine. These collaborations aim to advance paediatric oncology, gene therapy, and translational research. 🌍💉
#SyenzaNews #HealthcareInnovation #PaediatricOncology #GeneTherapy #TranslationalResearch #AbuDhabiHealthcare
Read more about how these partnerships are set to transform healthcare in Abu Dhabi and beyond.
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
